John Kirby Biography and Net Worth

CFO of Verrica Pharmaceuticals

Effective November 5, 2024, Mr. Kirby joined the company as Interim Chief Financial Officer. Prior to joining Verrica, Mr. Kirby served as an independent consulting Chief Financial Officer to publicly traded, development stage life science companies. Previously, Mr. Kirby served as the Chief Financial Officer of Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc. (“Idera”)) from September 2022 to April 2023 after serving as Idera’s Chief Financial Officer from July 2019 to September 2022, Vice President of Finance from 2018 to 2019 and Vice President of Corporate Accounting from 2015 to 2018. Prior to joining Idera, Mr. Kirby served as Assistant Controller at Endo Pharmaceuticals, Inc. from 2014 to 2015 and Vice President, Chief Accounting Officer and Corporate Controller at ViroPharma Incorporated from 2012 to 2014. Mr. Kirby began his career at KPMG, LLP in its Healthcare and Life Science Practice and served as a Regional Audit Director at AstraZeneca Pharmaceuticals L.P. prior to joining ViroPharma Incorporated. Mr. Kirby earned his BS in Accountancy from Villanova University and is a licensed certified public accountant in the Commonwealth of Pennsylvania.

What is John J. Kirby's net worth?: The estimated net worth of John J. Kirby is at least $41.44 thousand as of November 25th, 2025. Mr. Kirby owns 8,962 shares of Verrica Pharmaceuticals stock worth more than $41,440 as of September 18th. This net worth approximation does not reflect any other assets that Mr. Kirby may own. Learn More about John J. Kirby's net worth.
How do I contact John J. Kirby?: The corporate mailing address for Mr. Kirby and other Verrica Pharmaceuticals executives is 44 West Gay Street, Suite 400, West Chester, PA. Verrica Pharmaceuticals can also be reached via phone at (484) 453-3300 and via email at [email protected]. Learn More on John J. Kirby's contact information.
Has John J. Kirby been buying or selling shares of Verrica Pharmaceuticals?: John J. Kirby has not been actively trading shares of Verrica Pharmaceuticals during the past quarter. Most recently, on Tuesday, November 25th, John J. Kirby bought 3,536 shares of Verrica Pharmaceuticals stock. The stock was acquired at an average cost of $4.24 per share, with a total value of $14,992.64. Following the completion of the transaction, the chief financial officer now directly owns 8,962 shares of the company's stock, valued at $37,998.88. Learn More on John J. Kirby's trading history.
Who are Verrica Pharmaceuticals' active insiders?: Verrica Pharmaceuticals' insider roster includes Matt Davidson (Major Shareholder), A. Davis (CFO), Christopher Hayes (Insider), John Kirby (CFO), Paul Manning (Director), Jayson Rieger (CEO), Noah Rosenberg (CMO), Ted White (CEO), and David Zawitz (COO). Learn More on Verrica Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Verrica Pharmaceuticals?: During the last year, Verrica Pharmaceuticals insiders bought shares 9 times. They purchased a total of 4,247,576 shares worth more than $18,017,266.64. The most recent insider tranaction occured on August, 18th when CMO Noah L. Rosenberg bought 2,030 shares worth more than $9,987.60. Insiders at Verrica Pharmaceuticals own 52.9% of the company. Learn More about insider trades at Verrica Pharmaceuticals.
Information on this page was last updated on 8/18/2026.

John J. Kirby Insider Trading History at Verrica Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/25/2025	Buy	3,536	$4.24	$14,992.64	8,962

John J. Kirby Buying and Selling Activity at Verrica Pharmaceuticals

Verrica Pharmaceuticals Company Overview

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Today's Range

Now: $4.52

$4.56

$4.74

50 Day Range

MA: $5.22

$4.53

$6.26

2 Week Range

Now: $4.52

$3.28

$9.82

Volume

18,800 shs

Average Volume

93,034 shs

Market Capitalization

$77.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49